Status:
COMPLETED
Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19
Lead Sponsor:
Hospital San Carlos, Madrid
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Fatigue is common and disabling in patients with post-COVID syndrome. There is no treatment available at this moment, and fatigue has important consequences. The main aim of this study is to evaluate ...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 with PCR-confirmation.
- Fatigue linked to COVID-19
- No diagnosis of neurological, psychiatric or medical disorder with potential impact on fatigue.
Exclusion
- Stroke before COVID-19
- History of traumatic brain lesion or central nervous system infection previous to COVID-19
- Radiotherapy or chemotherapy for cancer
- Severe sensorial deficits
- Drugs or uncontrolled medical disorder with potential impact on fatigue.
- History of abuse of alcohol or other toxics.
- Any contraindication for tDCS (metallic implants, brain devices, pacemakers, head injuries).
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05252481
Start Date
April 1 2022
End Date
July 31 2022
Last Update
August 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico San Carlos.
Madrid, Spain, 28040